1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Petit, M.C.
Benkirane, N.
Guichard, G.
Phan Chan Du, A.
Cung, M.T.
Briand, J.P.
Muller, S.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C2 H4 O
44.053
ACETYL GROUP
non-polymer
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
274
3686
3692
10.1074/jbc.274.6.3686
9920919
Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site. Structural basis for its antigenic cross-reactivity with the parent peptide.
1999
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1972.235
PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS
1
man
polymer
no
yes
(ACE)GSGVRGDFGSLAPRVARQL
XGSGVRGDFGSLAPRVARQL
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conf
repository
Initial release
Version format compliance
Version format compliance
Derived calculations
Other
1
0
1998-11-25
1
1
2008-03-24
1
2
2011-07-13
1
3
2017-11-29
_pdbx_database_status.process_site
Y
BNL
1998-05-03
REL
G-H LOOP OF THE PROTEIN VP1
sample
target function
50
10
COSY
TOCSY
ROESY
NOESY
0.1M PHOSPHATE
5.7
1
atm
285
K
RESTRAINED ENERGY REFINEMENT.
torsion angle dynamics
H2O
GUNTERT,WUTHRICH
refinement
DYANA
1.4
structure solution
DYANA-1.4
400
Bruker
DRX400
ACE
140
n
1
ACE
140
A
GLY
141
n
2
GLY
141
A
SER
142
n
3
SER
142
A
GLY
143
n
4
GLY
143
A
VAL
144
n
5
VAL
144
A
ARG
145
n
6
ARG
145
A
GLY
146
n
7
GLY
146
A
ASP
147
n
8
ASP
147
A
PHE
148
n
9
PHE
148
A
GLY
149
n
10
GLY
149
A
SER
150
n
11
SER
150
A
LEU
151
n
12
LEU
151
A
ALA
152
n
13
ALA
152
A
PRO
153
n
14
PRO
153
A
ARG
154
n
15
ARG
154
A
VAL
155
n
16
VAL
155
A
ALA
156
n
17
ALA
156
A
ARG
157
n
18
ARG
157
A
GLN
158
n
19
GLN
158
A
LEU
159
n
20
LEU
159
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
SER
142
-99.15
59.47
1
A
VAL
144
175.11
116.49
1
A
ALA
156
-139.59
-46.25
2
A
SER
142
-51.61
173.49
2
A
VAL
144
175.10
116.47
2
A
ALA
156
-139.55
-46.25
3
A
VAL
144
175.03
116.43
3
A
ASP
147
-47.36
159.86
3
A
ARG
154
-111.01
71.12
3
A
ALA
156
-139.58
-46.25
4
A
VAL
144
175.07
116.49
4
A
ARG
145
-39.81
112.61
4
A
ALA
156
-139.62
-46.17
5
A
VAL
144
175.09
116.46
5
A
ARG
145
-166.49
107.71
5
A
ALA
156
-139.68
-46.23
6
A
SER
142
-113.16
59.64
6
A
VAL
144
175.10
116.47
6
A
PHE
148
-46.61
172.44
6
A
ALA
156
-139.61
-46.21
7
A
VAL
144
175.07
116.49
7
A
PHE
148
-41.69
158.69
7
A
LEU
151
-45.06
165.08
7
A
ALA
156
-139.60
-46.20
8
A
VAL
144
175.07
116.46
8
A
ARG
154
-151.83
88.96
8
A
ALA
156
-139.81
-46.26
9
A
SER
142
-151.85
55.22
9
A
VAL
144
175.07
116.46
9
A
ARG
145
-167.82
96.95
9
A
ALA
156
-140.47
-45.90
10
A
SER
142
-167.47
58.93
10
A
VAL
144
175.06
116.48
10
A
ARG
145
-56.49
106.06
10
A
ALA
156
-140.48
-45.86
model building
DYANA
refinement
DYANA
PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS
SYNTHETIC PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS, NMR, 10 STRUCTURES
1
Y
N
covale
1.325
A
ACE
140
A
C
ACE
1
1_555
A
GLY
141
A
N
GLY
2
1_555
SYNTHETIC PEPTIDE
SYNTHETIC PEPTIDE, ANTIGENE
POLG_FMDVA
UNP
1
1
P03308
MNTTNCFIALVHAIREIRAFFLSRATGKMEFTLYNGERKTFYSRPNNHDNCWLNTILQLFRYVDEPFFDWVYNSPENLTL
AAIKQLEELTGLELHEGGPPALVIWNIKHLLQTGIGTASRPARCMVDGTNMCLADFHAGIFLKEQEHAVFACVTSNGWYA
IDDEDFYPWTPDPSDVLVFVPYDQEPLNGGWKANVQRKLKGAGQSSPATGSQNQSGNTGSIINNYYMQQYQNSMDTQLGD
NAISGGSNEGSTDTTSTHTTNTQNNDWFSKLASSAFTGLFGALLADKKTEETTLLEDRILTTRNGHTTSTTQSSVGVTYG
YSTEEDHVAGPNTSGLETRVVQAERFFKKFLFDWTPDKPFGHRTKLELPTDHHGVFGHLVDSYAYMRNGWDVEVSAVGNQ
FNGGCLLVAMVPEWKTFDTREEYQLTLFPHQFISPRTNMTAHITVPYLGVNRYDQYKKHKPWTLVIMVLSPLTVSNTAAT
QIKVYANIAPTYVHVAGELPSKVGIFPVACSDGYGGLVTTDPKTADPVYGKEYNPPKTNYPRRFTNLLDVAEACPTFLCF
DDGKPYVVTRTDDTRLLAKFDVSLAAKHMSNTYLSGIAQYYTQYSGTINLHFMFTGSTDSKARYMVAYIPPGVETPPETP
EGAAHCIHAEWDTGLNSKFTFSIPYVSAADYAYTASDTAETTNVQGWVCIYQITHGKAEDDTLVVSASAGKDFELRLPID
PRSQTTATGESADPVTTTVENYGGETQVQRRHHTDVSFIMDRFVKIKSLNPTHVIDLMQTHQHGLVGALLRAATYYFSDL
EIVVRHDGNLTWVPNGAPEAALSNTGNPTAYNKAPFTRLALPYTAPHRVLATVYNGTNKYSASGSGVRGDFGSLAPRVAR
QLPASFNYGAIKAETIHELLVRMKRAELYCPRPLLAIEVSSQDRHKQKIIAPGKQLLNFDLLKLAGDVESNPRPFFFADV
RSNFSKLVDTINQMQEDMSTKHGPDFNRLVSAFEELATGVKAIRTGLDEAKPWYKLIKLLSRLSCMAAVAARTKDPVLVA
IMLADTGLEILDSTFVVKKISDSLSSLFHVPAPVFSFGAPVLLAGLVKVASSFLRSTPEDLERAEKQLKARDINDIFAIL
KNGEWLVKLILAIRDWIKAWIASEEKFVTMTDLVLGILEKQRDLNDPSKYKEAKEWLDNARQACLKSGNVHIANLCKVVA
PAPSKSRPEPVVVCLRGKSGQGKSFLANVLAQAISTHFTGRTDSVWYCPPDPDHFDGYNQQTVVVMDDLGQNPDGKDFKY
FAQMVSTTGFIPPMASLEDKGKPFNSKVIIATTNLYSGFTPRTMVCPDALNRRFHFDIDVSAKDGYKINNKLDIVKALED
THTNPVAMFQYDCALLNGMAVEMKRMQQDMFKPQPPLQNVYQLVQEVIERVELHEKVSSHPIFKQISIPSQKSVLYFLIE
KGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLLANIVIMIRETRKRQKMVDDAVNEYIE
KANITTDDTTLDEAEKNPLETSGASTVGFRERTLTGQRACNDVNSEPARPAEEQPQAEGPYTGPLERQRPLKVRAKLPQQ
EGPYAGPLERQKPLKVKAKAPVVKEGPYEGPVKKPVALKVKAKNLIVTESGAPPTDLQKMVMGNTKPVELILDGKTVAIC
CATGVFGTAYLVPRHLFAEKYDKIMLDGRAMTDSDYRVFEFEIKVKGQDMLSDAALMVLHRGNRVRDITKHFRDTARMKK
GTPVVGVVNNADVGRLIFSGEALTYKDIVVCMDGDTMPSLFAYKAATKAGYCGGAVLAKDGADTFIVGTHSAGGNGVGYC
SCVSKSMLLRMKAHVDPEPQHEGLIVDTRDVEERVHVMRKTKLAPTVAHGVFNPEFGPAALSNKDPRLNEGVVLDEVIFS
KHKGDTKMSAEDKALFRACAADYASRLHSVLGTANAPLSIYEAIKGVDGLDAMESDTAPGLPWAFQGKRRGALIDFENGT
VGPEVEAALKLMEKREYKFVCQTFLKDEIRPMEKVRAGKTRIVDVLPVEHILYTRMMIGRFCAQMHSNNGPQIGSAVGCN
PDVDWQRFGTHFAQYRNVWDVDYSAFDTNHCSDAMNIMFEEVFRTDFGFHPNAEWILKTLVNTEHAYENKRITVEGGMPS
DCSATGIINTILNNIYVLYALRRHYEGVELDTYTMISYGDDIVVASDYDLDFEALKPHFKSLGQTITPADKSDKGFVLGH
SITDVTFLKRHFHIDYGTGFYKPVMASKTLEAILSFARRGTIQEKLTSVAGLAVHSGPDEYRRLFEPFQGLFEIPSYRSL
YLRWVNAVCGDA
864
882
1BCV
141
159
P03308
A
1
2
20
1
P 1